TransCOVID: Does Gender-Affirming Hormone Therapy Play a Role in Contracting COVID-19?
J Sex Marital Ther
; 48(4): 415-426, 2022.
Article
in English
| MEDLINE | ID: covidwho-1528058
ABSTRACT
Based on the possible effects of androgens on the course of COVID-19, it can be posited that Gender-Affirming Hormone Therapy (GAHT) may affect the course of the disease in people with GD. We aimed to investigate the relationship between GAHT and contracting COVID-19, as well as the severity of the disease in individuals with Gender Dysphoria (GD). The single center, cross-sectional, web-based survey was completed by people with GD who received GAHT. The questionnaire contained three parts a sociodemographic data form; a GAHT data form; a COVID-19-related data form. Of the 238 participants, 179 were individuals with female-to-male (FtM) and 59 male-to-female (MtF) GD. We detected that the risk of contracting COVID-19 increased 3.46 times in people with FtM GD, who had received testosterone therapy, in comparison to people with MtF GD, who received estrogen and anti-androgen therapy. Additionally, people with FtM GD who contracted COVID-19 had received longer testosterone therapy when compared to those who did not contract COVID-19. Our findings indicate that individuals with FtM GD who receive testosterone treatment within the scope of GAHT are at higher risk of contracting COVID-19 and that the clinicians who follow-up on GAHT should be more careful about this issue.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Transgender Persons
/
Gender Dysphoria
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
J Sex Marital Ther
Year:
2022
Document Type:
Article
Affiliation country:
0092623X.2021.2000535
Similar
MEDLINE
...
LILACS
LIS